Proposed changes to ABPI Code of practice could hurt smaller firms, warns EMIG
This article was originally published in Scrip
Proposed changes to the ABPI (Association of the British Pharmaceutical Industry) code of practice, now out for consultation, could help improve transparency in the pharmaceutical industry. But plans to limit branded giveaways to healthcare professionals could disproportionately hurt smaller firms, making the code "unfit for purpose", warns the Ethical Medicines Industry Group, EMIG.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.